Childhood Chemotherapy Increases Later Cancer Risk

How Platinum Chemotherapy Alters Pediatric DNA

Platinum-based drugs combat cancer by actively damaging malignant cell DNA. Unfortunately, according to the research published in Science, the systemic treatment also leaves a heavy mutation footprint on healthy tissue. Investigators utilized a sophisticated DNA sequencing technique called NanoSeq to sample liver tissue—both healthy and cancerous—along with patient blood samples. They discovered that exposure to platinum agents triggers an average of 2,200 mutations per liver sample, a mutational burden typically observed in adult livers. In short, the chemotherapy effectively ages the liver cells of treated children.

Comparing Cellular Impact: Liver Versus Blood

While chemotherapy circulates throughout the entire body, the study revealed a striking discrepancy between different tissue types. Liver cells displayed significantly more mutations than blood cells in the same patients. “The platinum is doing something differently to liver cells than other cells. Either it’s been metabolized differently or the liver cells are repairing differently, we don’t really know yet,” said Foad Rouhani, an author of the paper and a professor at King’s College in London. This heightened vulnerability means the liver either processes the drug uniquely or carries pre-existing susceptibilities that drew illness initially.

Implications for Future Pediatric Cancer Survivorship

The discovery of widespread liver cell mutations does not mean patients will automatically develop secondary complications. “We found lots of cancer genes but also genes associated with long-term changes in liver metabolism,” Rouhani noted, emphasizing that “by no means does that mean that these cells will definitely become cancerous in time. All we talk about is there was evidence for potential for these cells to eventually cause problems further down the line.” In a separate perspective article, Baylor College of Medicine professors Sanjeev Vasudevan and Donald Williams Parsons wrote that these findings “provide strong evidence for conducting survivorship studies of children that have undergone treatment for liver cancer beyond their third decade of life.”

Redesigning Next-Generation Cancer Therapies

For clinicians, establishing that this cellular damage occurs opens the door to more targeted lifetime monitoring, allowing care teams to catch secondary issues much earlier. Beyond post-treatment surveillance, researchers hope these insights will reshape how cancer drugs are engineered. “If we understand the mechanism, can we then eventually be able to design next-generation chemotherapies which are highly effective at treating the cancer but actually leave the background tissue largely untouched?” Rouhani asked.

Frequently Asked Questions

What are platinum-based chemotherapies used for in children?

Drugs like cisplatin and carboplatin are vital treatments for childhood solid tumors, notably hepatoblastoma, where they have helped elevate localized survival rates beyond 80%.

Do platinum-based drugs cause cancer later in life?

While they introduce thousands of mutations into healthy liver cells—effectively aging the tissue—researchers stress this only establishes a potential risk for secondary tumors or liver pathologies, not a certainty.

Why did liver cells show more mutations than blood cells?

Scientists are still investigating, but they believe liver cells either metabolize platinum differently, repair DNA uniquely, or possess inherent susceptibilities that make them more reactive to the systemic treatment.